Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 194

Similar articles for PubMed (Select 19895942)

1.

The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.

Vergeer M, Stroes ES.

Am J Cardiol. 2009 Nov 16;104(10 Suppl):32E-8E. doi: 10.1016/j.amjcard.2009.09.017. Review.

PMID:
19895942
2.

Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.

Shinkai H.

Expert Opin Ther Pat. 2009 Sep;19(9):1229-37. doi: 10.1517/13543770903198451. Review.

PMID:
19663630
3.
4.

Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.

Blasi E, Bamberger M, Knight D, Engwall M, Wolk R, Winter S, Betts A, John-Baptiste A, Keiser J.

J Cardiovasc Pharmacol. 2009 Jun;53(6):507-16. doi: 10.1097/FJC.0b013e3181a8184c.

PMID:
19455053
5.

Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.

Mohammadpour AH, Akhlaghi F.

Clin Pharmacokinet. 2013 Aug;52(8):615-26. doi: 10.1007/s40262-013-0071-8.

6.

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.

Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ.

Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24. Erratum in: Circulation. 2009 Feb 10;119(5):e197.

7.

Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?

Neeli H, Rader DJ.

Cardiol Clin. 2008 Nov;26(4):537-46. doi: 10.1016/j.ccl.2008.06.005. Review.

PMID:
18929230
8.

The end of the road for CETP inhibitors after torcetrapib?

Joy T, Hegele RA.

Curr Opin Cardiol. 2009 Jul;24(4):364-71. Review.

PMID:
19522058
9.

Dalcetrapib: a review of Phase II data.

Robinson JG.

Expert Opin Investig Drugs. 2010 Jun;19(6):795-805. doi: 10.1517/13543784.2010.488219. Review.

PMID:
20465364
10.

JTT-705: is there still future for a CETP inhibitor after torcetrapib?

Rennings AJ, Stalenhoef A.

Expert Opin Investig Drugs. 2008 Oct;17(10):1589-97. doi: 10.1517/13543784.17.10.1589 . Review.

PMID:
18808319
11.

[HDL and CETP in atherogenesis].

Pöss J, Böhm M, Laufs U.

Dtsch Med Wochenschr. 2010 Feb;135(5):188-92. doi: 10.1055/s-0030-1247862. Epub 2010 Jan 15. Review. German.

PMID:
20082258
12.

Refocusing on use of cholesteryl ester transfer protein inhibitors.

Kastelein JJ.

Am J Cardiol. 2007 Dec 3;100(11 A):n47-52. Review.

PMID:
18047853
13.
14.

Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Barter P.

Am J Cardiol. 2009 Nov 16;104(10 Suppl):10E-5E. doi: 10.1016/j.amjcard.2009.09.014.

PMID:
19895939
15.

HDL metabolism and CETP inhibition.

Barkowski RS, Frishman WH.

Cardiol Rev. 2008 May-Jun;16(3):154-62. doi: 10.1097/CRD.0b013e31816a3b60.

PMID:
18414186
16.

Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?

Barter P, Rye KA.

Trends Pharmacol Sci. 2011 Dec;32(12):694-9. doi: 10.1016/j.tips.2011.07.004. Epub 2011 Nov 14. Review.

PMID:
22088767
17.

Spotlight on HDL-raising therapies: insights from the torcetrapib trials.

Kontush A, Guérin M, Chapman MJ.

Nat Clin Pract Cardiovasc Med. 2008 Jun;5(6):329-36. doi: 10.1038/ncpcardio1191. Epub 2008 Apr 22. Review.

PMID:
18431367
18.

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits.

Morehouse LA, Sugarman ED, Bourassa PA, Sand TM, Zimetti F, Gao F, Rothblat GH, Milici AJ.

J Lipid Res. 2007 Jun;48(6):1263-72. Epub 2007 Feb 26.

19.

Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.

Sofat R, Hingorani AD, Smeeth L, Humphries SE, Talmud PJ, Cooper J, Shah T, Sandhu MS, Ricketts SL, Boekholdt SM, Wareham N, Khaw KT, Kumari M, Kivimaki M, Marmot M, Asselbergs FW, van der Harst P, Dullaart RP, Navis G, van Veldhuisen DJ, Van Gilst WH, Thompson JF, McCaskie P, Palmer LJ, Arca M, Quagliarini F, Gaudio C, Cambien F, Nicaud V, Poirer O, Gudnason V, Isaacs A, Witteman JC, van Duijn CM, Pencina M, Vasan RS, D'Agostino RB Sr, Ordovas J, Li TY, Kakko S, Kauma H, Savolainen MJ, Kesäniemi YA, Sandhofer A, Paulweber B, Sorli JV, Goto A, Yokoyama S, Okumura K, Horne BD, Packard C, Freeman D, Ford I, Sattar N, McCormack V, Lawlor DA, Ebrahim S, Smith GD, Kastelein JJ, Deanfield J, Casas JP.

Circulation. 2010 Jan 5;121(1):52-62. doi: 10.1161/CIRCULATIONAHA.109.865444. Epub 2009 Dec 21. Erratum in: Circulation. 2010 Feb 23;121(7):e216.

20.

The failure of torcetrapib: what have we learned?

Joy TR, Hegele RA.

Br J Pharmacol. 2008 Aug;154(7):1379-81. doi: 10.1038/bjp.2008.248. Epub 2008 Jun 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk